Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 7, 2004, Pages 407-413

  Imanishi, Toshio ^a   Hano, Takuzo ^a   Sawamura, Tatsuya ^b   Nishio, Ichiro ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Endothelial progenitor cells; Oxidized low density lipoprotein; Senescence; Telomerase activity

Indexed keywords

ATORVASTATIN; BETA GALACTOSIDASE; LECTIN RECEPTOR; MATRIGEL; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1 ANTIBODY; RECEPTOR ANTIBODY; TELOMERASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BLOOD; BONE MARROW; CELL AGING; CELL CULTURE; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; CORONARY RISK; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MITOGENESIS; POLYMERASE CHAIN REACTION; PROTEIN INDUCTION; PROTEIN ISOLATION; STAINING; STEM CELL; TELOMERE;

BETA-GALACTOSIDASE; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MITOGENS; OXIDATION-REDUCTION; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3843063565     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.04022.x     Document Type: Article

References (24)

1. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 1999; 85: 221-8.
2. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
3. Kalka C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl Acad. Sci. USA 2000; 97: 3422-7.
4. Assmus B, Schachinger V, Teupe C et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106: 3009-17.
5. Vasa M, Fichtlscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885-90.
6. Vasa M, Fichtischerer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 2001; 89: E1-7.
7. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997; 94: 1062-71.
8. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160-2.
9. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. Modified low density lipoproteins and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J. Clin. Invest. 1995; 95: 1262-70.
10. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein (a): Role of oxygen-derived radicals. Circulation 1995; 92: 1582-9.
11. Dimmeler S, Haendeler J, Galle J, Zeiher AM. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases: A mechanistic clue to the 'response to injury' hypothesis. Circulation 1997; 95: 1760-3.
12. Hill JM, Zalos G, Halcox JPJ et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 2003; 348: 593-600.
13. Harley CB, Futcher AB, Greider CW. Telomeres shorten during aging of human fibroblasts. Nature 1990; 345: 458-60.
14. Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp. Gerontol. 1992; 27: 383-9.
15. Greider CW. Telomeres, telomerase and senescence. Bioassays 1990; 12: 363-9.
16. Murasawa S, Llevadot J, Silver M, Isner JM, Losordo DW, Asahara T. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation 2002; 106: 1133-9.
17. Breitschopf K, Zeiher AM, Dimmeler S. Pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism. FEBS Lett. 2001; 493: 21-5.
18. Heinecke JW, Baker L, Rosen H, Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J. Clin. Invest. 1986; 77: 757-61.
19. Dimmeler S, Aicher A, Vasa M et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J. Clin. Invest, 2001; 108: 391-7.
20. Imanishi T, Hano T, Matsuo Y, Nishio I. Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial progenitor cell differentiation. Clin. Exp. Pharmacol. Physiol. 2003; 30: 665-70.
21. Dimri GP, Lee X, Basile G et al. A biomarker that identifies senescent human cells in culture and in aging skin in vitro. Proc. Natl Acad. Sci. USA 1995; 92: 9363-7.
22. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol [TRAP]. Nucleic Acids Res. 1997; 25: 2595-7.
23. Li D, Mehta JL. Upreguladon of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells. Evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1116-22.
24. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev. 1999; 13: 2905-27.